Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Arresten: a potential biomarker and therapy for cancer

EF 2018-19

Résumé
The leading cause of cancer related deaths is due to metastasis of cancer, which is the spreading of cancer from a primary site to secondary sites. Additionally, detection of many types of cancer is difficult in early stages, and the cancer is usually not detected until it has metastasized. An essential component of metastasis is angiogenesis, which is the formation of new blood vessels, because forming new blood vessels allows for cancerous cells to spread to secondary sites in the body. Angiogenesis is influenced by many factors which either activate or inhibit the process. One factor that inhibits the process of angiogenesis is arresten. The level of arresten is activated by the protein p53. However, in many cancers, the gene encoding p53 is mutated which can limit the level or change the function of p53. As a result, the level of arresten changes and is limited, thereby limiting inhibition of angiogenesis. This study proposes investigating arresten protein levels in blood and urine samples from mice and humans, with and without cancer, to determine if arresten levels correlate with tumour prognosis and patient survival. If arresten levels do correlate with tumour prognosis and patient survival, then arresten has the potential to be used as a biomarker for cancer detection. Furthermore, this study proposes experiments to mutate the gene encoding arresten, in human cells, so that p53 can no longer affect arresten levels. These cells will be used for eventual injection into mice to create human tumours in mice to further characterize the effect of p53-dependent arresten on angiogenesis. If we can further characterize this effect, this research can be useful when determining if arresten could be used in cancer therapy.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
416079
Name
Nath Serena
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Arresten: a potential biomarker and therapy for cancer
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Angiogenesis; Arresten; Cancer; Col4a1; Crispr; Elisa; P53
Abstract
The leading cause of cancer related deaths is due to metastasis of cancer, which is the spreading of cancer from a primary site to secondary sites. Additionally, detection of many types of cancer is difficult in early stages, and the cancer is usually not detected until it has metastasized. An essential component of metastasis is angiogenesis, which is the formation of new blood vessels, because forming new blood vessels allows for cancerous cells to spread to secondary sites in the body. Angiogenesis is influenced by many factors which either activate or inhibit the process. One factor that inhibits the process of angiogenesis is arresten. The level of arresten is activated by the protein p53. However, in many cancers, the gene encoding p53 is mutated which can limit the level or change the function of p53. As a result, the level of arresten changes and is limited, thereby limiting inhibition of angiogenesis. This study proposes investigating arresten protein levels in blood and urine samples from mice and humans, with and without cancer, to determine if arresten levels correlate with tumour prognosis and patient survival. If arresten levels do correlate with tumour prognosis and patient survival, then arresten has the potential to be used as a biomarker for cancer detection. Furthermore, this study proposes experiments to mutate the gene encoding arresten, in human cells, so that p53 can no longer affect arresten levels. These cells will be used for eventual injection into mice to create human tumours in mice to further characterize the effect of p53-dependent arresten on angiogenesis. If we can further characterize this effect, this research can be useful when determining if arresten could be used in cancer therapy.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Nath, Serena
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~